P214 What is the diagnostic accuracy of faecal calprotectin regarding endoscopic relapse in Crohn's disease patients following ileocecal resection? A tertiary single center experience

Background

There is still some discrepancy about the accuracy of faecal calprotectin (FC) in Crohn's disease (CD) patients after ileocecal resection and data from real daily practise on this topic is still scarce.

Methods

For this purpose we prospectively gathered the simultaneous FC results of CD patients who were referred to the endoscopy unit in the postoperative (postop) setting. Patients with upper GI involvement were excluded. Demographic data like age, sex, disease duration, Rutgeerts score, FC, CRP results were all noted. All patients gave a stool sample 24 hours before colonoscopy and FC was determined via ELISA (Quantum Blue Calprotectin, Bühlmann Lab. AG, Switzerland).

Results

Seventy-four CD patients [38 female (51%)] with an ileoceal resection were enrolled into the study protocol. Their mean age was 38.56±12 yr. with a mean disease duration of 123.52±84.88 mo. Fourty-four of 74 (60%) patients were in endoscopic remission whereas 30 (40%) had endoscopic relapse [i0- 31 patients (42%); i1- 13 patients (18%), i2- 11 patients (15%), i3- 14 patients (19%), i4- 5 patients (6%)]. Nonparametric Spearman correlation test only revealed that FC using a cut off of 30 μg/g weakly correlated with endoscopic relapse (r=0.329, p=0.004). Diagnostic accuracies of FC using different cut offs is shown in Table 1.

Table 1 Diagnostic performance of FC regarding endoscopic relapse using different cut offs